Actively Recruiting
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Led by Eisai Co., Ltd. · Updated on 2026-02-27
60
Participants Needed
1
Research Sites
384 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to investigate the safety of Tasfygo.
CONDITIONS
Official Title
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naive to Tasfygo tablet and progressed after chemotherapy.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
#Eisai Trial Site 1
Tokyo, Japan
Actively Recruiting
Research Team
E
Eisai Inquiry Service
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here